linjc16/ctgov huggingface dataset:
Genetic Contributions to Autism Spectrum Disorders

Study Overview
=================
Brief Summary
-----------------
This study is working towards gaining a better understanding of the genetic and environmental factors involved in autism spectrum disorders (ASD), which includes autism, pervasive developmental disorder (PDD), and Asperger's syndrome. The investigators hope that information gained from this study will lead to new ways of diagnosing and treating ASDs.

Detailed Description
-----------------
Participation generally takes less than 2 hours to complete and travel to Children's Hospital Boston is not required. Participants are asked some questions about their medical and family history. The investigators also request permission to review medical records related to the ASD diagnosis. Finally, the investigators obtain a small blood or saliva sample in order to search for genes that may be important in understanding ASD. The investigators can arrange for the blood draw through a participant's physician or a clinical laboratory and saliva samples can be obtained through the mail. The study questions are answered via telephone or mailed questionnaires. There is no cost to participate.

Official Title
-----------------
Genetic Contributions to Autism Spectrum Disorders

Conditions
-----------------
Autism Spectrum Disorder, Autism, Asperger's Syndrome, Pervasive Developmental Disorder

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of an Autism Spectrum Disorder (autism, pervasive developmental disorder (PDD), or Asperger's syndrome) Age > 18 months Exclusion Criteria: Do not have the diagnosis of an ASD Participation in the Phenotypic and Genetic Risk Factors in ASD study at Boston Children's Hospital.

Ages Eligible for Study
-----------------
Minimum Age: 18 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Gene expression levels | Gene expression levels | At sample collection | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Autism, Asperger's Syndrome, Asperger Syndrome, Autistic Disorder, Autism Spectrum Disorder, Pervasive Developmental Disorders, Pervasive Developmental Disorder-Not Otherwise Specified, Child Development Disorders, Pervasive, PDD-NOS
Imaging Template for Reporting Anal Fistula

Study Overview
=================
Brief Summary
-----------------
Magnetic resonance imaging (MRI) is the most used diagnostic tool for pre-operative assessment of anal fistula. However, there is lack of standardization in reporting this investigation. Moreover, reports may miss a number of key information for surgical planning. The aim of this study is to assess the effectiveness, reproducibility, and acceptability of a new template for reporting anal fistula, which may favor standardization in clinical practice and inform surgical decision making.

Official Title
-----------------
Imaging Template for Reporting Anal Fistula

Conditions
-----------------
Anal Fistula

Intervention / Treatment
-----------------
* Diagnostic Test: MRI


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults with primary anal fistula (cryptoglandular or Crohn-related) undergoing MRI Exclusion Criteria: Active cancer of the anorectum Recto-vaginal fistula

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Novel template report<br>The last 100 consecutive and anonymized MRI investigations for primary perianal fistula reported according to standard practice by dedicated radiologists (the last 10 reports from each of 10 international centers) are reviewed blindly and independently by two experienced radiologists (based on case load, years of experience and publications on anal fistula) using a novel template incorporating 8 key descriptors. A third independent experienced radiologist will resolve any disagreement and assess the presence of descriptors in the original report compared to the novel template. | Diagnostic Test: MRI<br>* Magnetic resonance imaging<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Effectiveness of the novel template compared to standard reporting based on the number of key descriptors |  | 60 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Inter-rater agreement between two independent experienced radiologists using the novel template |  | 7 days | 
| Qualitative analysis | The 100 MRI investigations (100 original reports and 100 using the novel template) are sent to 20 experienced surgeons (10 randomly selected reports per surgeon, of which 5 reported conventionally and 5 using the novel template), who will complete a semistructured e-mail interview to collect in-depth information about any barriers and facilitators to implementation of the novel template, and ultimately explore surgical decision making. | 30 days |
Association of T1-mapping and LV Strain Analysis by CMR

Study Overview
=================
Brief Summary
-----------------
The association of T1-mapping (both native and ECV) and strain analysis of LV and RV by CMR will be assessed. Results from strain analysis will be investigated in terms of their prognostic value.

Official Title
-----------------
Association of T1-mapping and LV Strain Analysis by CMR

Conditions
-----------------
Myocardial Fibrosis

Intervention / Treatment
-----------------
* Diagnostic Test: Strain analysis by CMR


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: undergoing CMR willingness to participate Exclusion Criteria: <18 years old pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| ECV < median<br> | Diagnostic Test: Strain analysis by CMR<br>* Strain analysis by CMR will be performed<br>|
| ECV ≥ median<br> | Diagnostic Test: Strain analysis by CMR<br>* Strain analysis by CMR will be performed<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Association of native LV T1-values and strain analysis | Association of native LV T1-values and strain analysis by CMR | Baseline | 
| Association of ECV and strain analysis | Association of ECV and strain analysis by CMR | Baseline | 
| Association of strain analysis and outcome | Association of strain analysis by CMR and outcome (combination of cardiovascular hospitalization or death) | 2 years |
Outcome of COVID-19 Cases Based on Tuberculin Test: Can Previous BCG Alter the Prognosis?

Study Overview
=================
Brief Summary
-----------------
There is no evidence that the Bacille Calmette-Guérin vaccine (BCG) protects people against infection with COVID-19 virus. Two clinical trials addressing this question are underway, and WHO will evaluate the evidence when it is available. In the absence of evidence, WHO does not recommend BCG vaccination for the prevention of COVID-19. WHO continues to recommend neonatal BCG vaccination in countries or settings with a high incidence of tuberculosis. There is experimental evidence from both animal and human studies that the BCG vaccine has non-specific effects on the immune system. These effects have not been well characterized and their clinical relevance is unknown

Official Title
-----------------
Outcome of COVID-19 Cases Admitted to Hospital and ICU With Positive Tuberculin Test: Can Previous BCG Alter the Prognosis?

Conditions
-----------------
COVID-19, BCG Vaccination

Intervention / Treatment
-----------------
* Diagnostic Test: Tuberculin test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: COVID-19 positive cases admitted to hospitals in Upper Egypt Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group A<br>COVID-19 positive with positive tuberculin test | Diagnostic Test: Tuberculin test<br>* Test the delayed hypersensitivity reaction and immunity to previous BCG vaccination<br>|
| Group B<br>COVID-19 positive with negative tuberculin test | Diagnostic Test: Tuberculin test<br>* Test the delayed hypersensitivity reaction and immunity to previous BCG vaccination<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pneumonia severity index | severity of COVID-19 pneumonia | 2 weeks | 
| Need for ICU admission | severe pneumonia indicating invasive or non invasive mechanical ventilation | 2 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| COVID -19 test conversion | number of days to cure from COVID-19 disease | 2 weeks | 
| Mortality | frequency of fatalities | 2 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Outcome, COVID-19 pneumonia, BCG, Tuberculin test positive, Egypt
Evaluation of Electrocardiography Performed With Mobile ECG Devices in Cardiac Patients and Healthy Volunteers

Study Overview
=================
Brief Summary
-----------------
Electrocardiography is one of most basic laboratory tests in cardiology. Novel mobile ECG are becoming popular. The investigators aim to compare typical electrocardiographic measurements obtained with mobile ECG devices (Alivecor Kardia and Alivecor Cardia 6L) and 12-leads standard ECG (gold standard). The recordings will be compared by cardiologist paying special attention to heart rhythm disturbances, components of ECG curve and quality of recording.

Detailed Description
-----------------
Electrocardiography is one of most basic laboratory tests in cardiology. Novel mobile ECG are becoming popular. The investigators aim to compare typical electrocardiographic measurements obtained with mobile ECG devices (Alivecor Kardia and Alivecor Cardia 6L) and 12-leads standard ECG (gold standard). The recordings will be compared by cardiologist paying special attention to heart rhythm disturbances, components of ECG curve and quality of recording. ECG evaluation will include: rhythm description, measurements of mean RR, PR, QRS, QT, QTc and ST-T description. Additionally inter/intraventricular conduction abnormalities are to be determined from 12-leads ECG and approximate from mobile ECG recordings.

Official Title
-----------------
Evaluation of Electrocardiography Performed With Mobile ECG Devices in Cardiac Patients and Healthy Volunteers

Conditions
-----------------
Cardiac Arrhythmia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with indication for electrocardiography Informed consent to participate in the study The possibility of self-registration of a mobile ECG (no physical and mental restrictions) Exclusion Criteria: Not willing or incapable to give written informed consent. Lack of willingness to cooperate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ECG Tracing Quality | Evaluation of quality of ECG tracings obtained with different electrocardiographs | Once: Day 0-3 after entry to the study. | 
| Cardiac Rhythm Determination | Defining a rhythm of the patient based on recorder tracings. | Once: Day 0-3 after entry to the study. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Electrocardiogram, Mobile ECG
Prevention of Postoperative Nausea and Vomiting (PONV) by Acupressure

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether stimulation to the akupressurpoint P6 with a recently developed bracelet are effective preventing postoperative nausea and vomiting

Official Title
-----------------
Prevention of PONV by Acupressure. A Study of the Effect of a Recently Generated Danish Bracelet Vital-Band(R) Which Stimulates the Acupressure Point P6

Conditions
-----------------
Postoperative Nausea and Vomiting, Acupressure Point P6

Intervention / Treatment
-----------------
* Device: Vital-band (R)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female, Non-smoker, >18 years, ASA 1 or 2, Signed patient information, IV-anaestesia. Exclusion Criteria: Male, Smoker, ASA 3 or 4, Pregnancy, Nausea and vomiting within the last 24 h before operation, Diabetes, Carpaltunnel syndrome, Lymphedema of arms, Eczema of forearm, Patients who earlier has undergone removal of lymph nodes in the armpits, Inhalation anaestesia.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Vital-band (R)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postoperative nausea and vomiting |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 1: The use of conventionel antiemetic treatment. |  |  | 
| 2: Lenght of stay in the perioperative unit. |  |  | 
| 3: overall lenght of stay |  |  |
Can the Thoracic Replace the Conventional Radiography for the Diagnosis of Acute Pneumonia in Children?

Study Overview
=================
Brief Summary
-----------------
The Thoracic ultrasound is a safer and sensitive technique than conventional radiography because it detects less than 1 cm pneumonic consolidations and minimal pleural effusions. The main objective is to evaluate the efficacy of thoracic ultrasound performed by unskilled personnel in the emergency service prdiatricas to diagnose pneumonia in children.

Detailed Description
-----------------
Diagnostic test evaluation.The sample collected sequentially until an exact size . Given the safety of the technique, which involves no risk to patient management and the possibility of generating a type II error by premature study discontinuation , we have no plans to make any interim analyzes .

Official Title
-----------------
Can the Thoracic Replace the Conventional Radiography for the Diagnosis of Acute Pneumonia in Children?

Conditions
-----------------
Pneumonia

Intervention / Treatment
-----------------
* Other: Thoracic ultrasound
* Other: CXR


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: fever above 38 degrees tachypnea Difficulty breathing Side tip pain pathological auscultation Exclusion Criteria: < 3 months> 14 years Background of Prematurity Rewalizados imaging studies in the last 7 days Any chronic respiratory process congenital heart diseases hemodynamic instability Diagnosis of pneumonia in the last 3 months Refusal of relatives to participate in the study

Ages Eligible for Study
-----------------
Minimum Age: 3 Months
Maximum Age: 14 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Candidates patients chest X-ray with pneumonia<br>thoracic sonography CXR Clinical control 48h | Other: Thoracic ultrasound<br> <br> Other: CXR<br> <br> |
| Other: Candidates patients chest X-ray without pneumonia<br>thoracic sonography CXR Clinical control 48h | Other: Thoracic ultrasound<br> <br> Other: CXR<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| coincidence between the ultrasound image and conventional radiography | images compatible with pneumonic consolidations in sonography and radiography . Coincidence between evaluators | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| additional workload | Time (minutes) between the test requested and the results are obtained for both diagnostic tests | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
thoracic ultrasound, children, efficacy, emergency service
The Impact of Exercise Training on Functional Capacity in Heart Failure

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether exercise training will improve functional capacity in patients with heart failure and preserved ejection fraction.

Official Title
-----------------
Impact of Exercise Training on Functional Capacity in Heart Failure Patients With Preserved Ejection Fraction.

Conditions
-----------------
Heart Failure With Preserved Ejection Fraction

Intervention / Treatment
-----------------
* Behavioral: Exercise training


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical heart failure Preserved ejection fraction (>50%) Stable clinically New York Heart Association Class II-III Exclusion Criteria: Unable to exercise Other debilitating or unstable disease limiting length of life Implanted pacemaker

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Exercise training<br>Protocol of 3 month exercise training program. | Behavioral: Exercise training<br>* Exercise training program for 3 months (two times a week).<br>|
| No Intervention: Control<br>Control group | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline of peak oxygen uptake on graded exercise. | Changes in physical fitness after 3 month exercise training. This will be measured by a cardiopulmonary exercise test with recording of maximal oxygen uptake during incremental exercise. | After 3 month exercise training | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline of six minute walk | Change in the distance covered during a 6 minute walk after 3 month exercise training. | After 3 month exercise training | 
| Change from baseline of NYHA class | Change in subjective assessment of function capacity based on the New York Heart Association Class classification after 3 month exercise training. | After 3 month exercise training | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
heart failure, preserved ejection fraction
Collecting Tissue Samples for Future Research From Women Undergoing Surgery for Breast Cancer

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Collecting and storing samples of tumor tissue from patients with breast cancer to study in the laboratory may help doctors learn more about cancer. PURPOSE: This phase I study is collecting tissue samples for future research from women undergoing surgery for breast cancer.

Detailed Description
-----------------
OBJECTIVES: Primary Collect breast tissue for future research from women undergoing surgery for breast cancer. Secondary Create microarrays by tumor type for internal use by Specialized Program of Research Excellence. OUTLINE: Tumor tissue is collected and analyzed to create microarrays by tumor type for future research studies. PROJECTED ACCRUAL: A total of 1,250 patients will be accrued for this study.

Official Title
-----------------
Specialized Program of Research Excellence (SPORE) in Breast Cancer: Tissue and Specimen Collection

Conditions
-----------------
Breast Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: Undergoing surgery for breast cancer
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Collect human breast tissues and associated clinical-pathologic data |  | At time of diagnosis, surgery, and throughout standard care and clinical follow-up. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
breast cancer